Se hai scelto di non accettare i cookie di profilazione e tracciamento, puoi aderire all’abbonamento "Consentless" a un costo molto accessibile, oppure scegliere un altro abbonamento per accedere ad ANSA.it.

Ti invitiamo a leggere le Condizioni Generali di Servizio, la Cookie Policy e l'Informativa Privacy.

Puoi leggere tutti i titoli di ANSA.it
e 10 contenuti ogni 30 giorni
a €16,99/anno

  • Servizio equivalente a quello accessibile prestando il consenso ai cookie di profilazione pubblicitaria e tracciamento
  • Durata annuale (senza rinnovo automatico)
  • Un pop-up ti avvertirà che hai raggiunto i contenuti consentiti in 30 giorni (potrai continuare a vedere tutti i titoli del sito, ma per aprire altri contenuti dovrai attendere il successivo periodo di 30 giorni)
  • Pubblicità presente ma non profilata o gestibile mediante il pannello delle preferenze
  • Iscrizione alle Newsletter tematiche curate dalle redazioni ANSA.


Per accedere senza limiti a tutti i contenuti di ANSA.it

Scegli il piano di abbonamento più adatto alle tue esigenze.

Sputnik vaccine to be made in Italy, 1st in EU

Sputnik vaccine to be made in Italy, 1st in EU

10 mn doses to be made in Italy by year's end

ROME, 09 March 2021, 14:04

Redazione ANSA

ANSACheck

- ALL RIGHTS RESERVED

-     ALL RIGHTS RESERVED
- ALL RIGHTS RESERVED

The Russian Sputnik COVID-19 vaccine is to be made in Italy, the first European Union country to do so, the Italo-Russian Chamber of Commerce announced Tuesday.
    "An agreement has been signed by the Russian government fund and the ADIENNE Pharma&Biotech company for the production of the Sputnik V vaccine in Italy," it said.
    It said the managing director of the Russian Direct Investment Fund (RDIF), Kirill Dmitriev, had confirmed an accord had been reached with ADIENNE Pharma&Biotech "sealing the first European contract for the local production of the vaccine".
    Sputnik production in Italy will start in July, it said.
    The chamber of commerce said Sputnik's "innovative production process" would help create new jobs and enable Italy to control the whole process of production.
    This will enable the production of some 10 million doses in Italy by the end of the year, it said.
    The accord had been reached by talks between Italian and Russian firms helped by the Italian embassy in Russia, the chamber said.
    Chamber Chairman Vincenzo Trani said "Italian firms are strategic, they have unique capacity and competencies on the European scene and are able to face the market with flexibility and speed".
    He said the accord was "historic".
    Trani said it showed "the healthy state of relations between our two countries and underscores how Italian companies know how to see beyond political polemics".
    Sputnik V is a COVID-19 vaccine developed by the Gamaleya Research Institute of Epidemiology and Microbiology.
    A recent published in The Lancet indicated 91.6% efficacy without unusual side effects.
    Emergency mass-distribution of the vaccine began in December 2020 in multiple countries including Russia, Argentina, Belarus, Hungary, Serbia and the United Arab Emirates.
    As of March 2021, forty-five countries have granted Sputnik V emergency use authorization, while over a billion doses of the vaccine were ordered for immediate distribution globally.
   
   

ALL RIGHTS RESERVED © Copyright ANSA

Not to be missed

Share

Or use

ANSA Corporate

If it is news,
it is an ANSA.

We have been collecting, publishing and distributing journalistic information since 1945 with offices in Italy and around the world. Learn more about our services.